Café

© 2026 Longbridge｜Terms of Service Privacy Policy

ZNTL

ZNTL

3.8250.39%( -0.015 )

LongbridgeAI

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

StockTitan

May 21, 2026 at 08:40 AM

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

Login to unlock227characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

ZeZentalis Pharma

USZNTL

-0.39%

iShares Biotechnology ETF

USIBB

SPDR S&P Biotech

USXBI